Evidence map›Paper›PMID 31184899›Full record

ArticleNano letters2019

Multiantigenic Nanotoxoids for Antivirulence Vaccination against Antibiotic-Resistant Gram-Negative Bacteria.

Xiaoli Wei, Danni Ran, Anaamika Campeau, Crystal Xiao, Jiarong Zhou, Diana Dehaini, Yao Jiang, Ashley V Kroll, Qiangzhe Zhang, Weiwei Gao and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nano letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 90 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Biomimetic cell membrane-coated poly(lactic-Bioengineering & translational medicine · 2023
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Xiaoli WeiDepartment of NanoEngineering and Chemical Engineering Program , University of California San Diego , La Jolla , California 92093 , United States.
Danni RanDepartment of NanoEngineering and Chemical Engineering Program , University of California San Diego , La Jolla , California 92093 , United States.
Anaamika CampeauDepartment of Pharmacology, Skaggs School of Pharmacy and Pharmaceutical Sciences , University of California San Diego , La Jolla , California 92093 , United States.
Crystal XiaoDepartment of NanoEngineering and Chemical Engineering Program , University of California San Diego , La Jolla , California 92093 , United States.
Jiarong ZhouDepartment of NanoEngineering and Chemical Engineering Program , University of California San Diego , La Jolla , California 92093 , United States.
Diana DehainiDepartment of NanoEngineering and Chemical Engineering Program , University of California San Diego , La Jolla , California 92093 , United States.
Yao JiangDepartment of NanoEngineering and Chemical Engineering Program , University of California San Diego , La Jolla , California 92093 , United States.
Ashley V KrollDepartment of NanoEngineering and Chemical Engineering Program , University of California San Diego , La Jolla , California 92093 , United States.
Qiangzhe ZhangDepartment of NanoEngineering and Chemical Engineering Program , University of California San Diego , La Jolla , California 92093 , United States.
Weiwei GaoDepartment of NanoEngineering and Chemical Engineering Program , University of California San Diego , La Jolla , California 92093 , United States.
David J GonzalezDepartment of Pharmacology, Skaggs School of Pharmacy and Pharmaceutical Sciences , University of California San Diego , La Jolla , California 92093 , United States.
Ronnie H FangDepartment of NanoEngineering and Chemical Engineering Program , University of California San Diego , La Jolla , California 92093 , United States.
Liangfang ZhangDepartment of NanoEngineering and Chemical Engineering Program , University of California San Diego , La Jolla , California 92093 , United States.ORCID 0000-0003-0637-0654
University of California San Diego · US

Funding

GRADUATE TRAINING IN CELLULAR &MOLECULAR PHARMACOLOGYT32GM007752 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROWN, JOAN HELLER, HANDEL, TRACY M · 1985 to 2023
$13.5M
Cancer Researchers in Nanotechnology (CRIN)T32CA153915 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KUMMEL, ANDREW CLYDE, ZHANG, DONG-ER · 2017 to 2021
$994k
NCI NIH HHS T32 CA153915NIGMS NIH HHS T32 GM007752
6 · The paper itself

Abstract

Infections caused by multidrug-resistant Gram-negative bacteria have emerged as a major threat to public health worldwide. The high mortality and prevalence, along with the slow pace of new antibiotic discovery, highlight the necessity for new disease management paradigms. Here, we report on the development of a multiantigenic nanotoxoid vaccine based on macrophage membrane-coated nanoparticles for eliciting potent immunity against pathogenic

Indexed as

Bacterial VaccinesDrug Resistance, BacterialPseudomonas InfectionsToxoidsVaccinationAnimalsImmunity, HumoralMicePseudomonas aeruginosaVirulence FactorsBacterial VaccinesToxoidsVirulence Factorsantivirulence vaccinationBiomimetic nanotechnologyGram-negative infectionnanotoxoid

Identifiers

PMID31184899
PMCPMC6711367
OpenAlexW2953315599

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.